Business
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAvant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health\n\n\n\n\n\nAvant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health\nCompanies to hold a Conference Call to discuss the business combination today, March 7, 2015 at 4:30pm ET\nPR Newswire\nSCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016\n\n\n\nSCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016 /PRNewswire/ --\n\nHighlights of Business Combination \n\n\nAmarantus Diagnostics and Theranostics Health operations to consolidate into Avant Diagnostics (OTCQB:AVDX)  \n\nTheranostics Health customer list includes 7 of the top 10 pharmaceutical companies with estimated pharma services revenue of over $1.5 million in 2015 expected to grow significantly in the coming years using \n\nCombined Company to forward rich pipeline of Oncology and Neurology diagnostics with 3 proprietary diagnostic tests for ovarian cancer (OvaDx®), multiple sclerosis (MSPrecise®) and Alzheimer's disease (LymPro Test®) CLIA-enabling validation studies for OvaDx® MSPrecise® and LymPro Test® expected to initiate in 2016 to support product launch in 2017 \n\nScientific focus is on becoming recognized leader in field of cell cycle biology research with Theralink® for oncology and LymPro Test® for Alzheimer's  \n\n\nAvant Diagnostics, Inc. (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc. (\"Amarantus Diagnostics\") a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (\"Amarantus BioScience\") (OTCQX: AMBS), today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated (\"THI\"), adding key CLIA laboratory and intellectual property capabilities to Avant's previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the \"Transactions\"). THI currently generates over $1.5M in services revenue from some of the world's leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination to...